Celularity Inc. Resolves Final Listing Compliance
The biotech firm cleared its remaining exchange deficiencies after filing two overdue quarterly financial reports.
Updated on Oct. 23, 2026 in Public Companies
Live Poll
Do you trust companies that repeatedly fail to meet their official financial reporting deadlines?
Nasdaq has closed the final outstanding listing compliance matter for Celularity Inc. following the company's submission of its overdue June-quarter financial report.
Why it matters
Operators must maintain rigorous financial reporting schedules to satisfy exchange requirements, as delays can threaten a company's public listing status and force costly organizational remediation.
Nasdaq resolved a total of 3 disclosed listing deficiencies for Celularity Inc. The company cleared these matters after filing its overdue reports for the quarters ending March 31 and June 30, 2026.
The players
Celularity Inc.
A clinical-stage biotechnology company developing placenta-derived cell therapies.
Nasdaq
A global stock exchange operator that enforces listing standards for publicly traded companies.
The details
Celularity Inc. triggered listing compliance reviews after failing to file its periodic financial reports with the Securities and Exchange Commission on time. Nasdaq Listing Rule 5250(c)(1) mandates these timely submissions for listed companies. To address the resulting deficiencies, the biotech firm initiated an overhaul of its internal finance organization to stabilize its reporting processes.
Timeline
August 21, 2026: Nasdaq issued a notice of non-compliance to Celularity.
September 11, 2026: Nasdaq closed deficiencies regarding minimum bid price and market value.
September 29, 2026: Celularity submitted its March 31, 2026, quarterly report.
October 20, 2026: Celularity submitted its June 30, 2026, quarterly report.
Market Landscape
This development marks a return to adherence with Nasdaq Listing Rule 5250(c)(1) regarding periodic reporting requirements. It follows a period of instability for Celularity Inc. that previously threatened its standing on the exchange.
Publicly traded firms should monitor their finance team's capacity to meet SEC filing deadlines to avoid costly notices from exchange regulators. The case highlights that administrative failures in reporting can trigger broad reviews of listing eligibility.
The takeaway
Maintaining timely financial reporting is a non-negotiable operational baseline for any firm managing public listing requirements. Executives should audit their financial reporting workflows to ensure they can meet SEC deadlines regardless of internal organizational changes.
Further reading
For more on the regulatory requirements for domestic firms, visit the Public Companies section.
Source note: This article includes information reported by TokenPost.
Live Poll
Do you trust companies that repeatedly fail to meet their official financial reporting deadlines?
